Skip to content

Intraoperative and Postoperative Outcomes of Three Ophthalmic Viscosurgical Devices During Phacoemulsification

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01664689
Enrollment
120
Registered
2012-08-14
Start date
2011-10-31
Completion date
2012-03-31
Last updated
2012-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intraoperative Performance and Postoperative Outcomes Following Cataract Surgery

Brief summary

Ophthalmic Viscosurgical Devices (OVDs) play a crucial role during phacoemulsification, by providing endothelial protection, maintaining space, as well as facilitating surgical maneuvers, including IOL implantation. Equally important is the ease of use, good visualisation and easy removal of the OVD from the eye. Currently, 3 popularly used OVDs as a single injection sufficing for surgery are: Healon 5, DiscoVisc, and Celoftal (2% hydroxypropylmethylcellulose). Whereas, there are studies showing efficacy of each of these in clinical scenarios, there is no randomized trial comparing intraoperative performance and postoperative outcomes. The aim of this study was to compare intraoperative performance and postoperative outcomes following microcoaxial phacoemulsification when using one of the three OVDs

Interventions

Sponsors

Iladevi Cataract and IOL Research Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
45 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Age related, uncomplicated senile cataracts

Exclusion criteria

* presence of glaucoma, * shallow anterior chamber (ACD \< 2.1mm), * pupillary dilatation \< 6mm, * extremely dense cataracts, * posterior polar cataract, * subluxated cataract, * white mature cataract, * diabetic retinopathy, * high myopia (defined as AL \> 25mm), * uveitis, or * previous ocular trauma/surgery.

Design outcomes

Primary

MeasureTime frame
Corneal clarity on postoperative day 1postoperative day 1

Secondary

MeasureTime frame
Central corneal thickness on postoperative day 1 and week 1day 1 and week 1

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026